Curis Inc Stock Investor Sentiment

CRIS Stock  USD 4.39  0.06  1.35%   
Slightly above 68% of Curis' investor base is looking to short. The analysis of the overall investor sentiment regarding Curis Inc suggests that many traders are alarmed. Curis' investing sentiment can be driven by a variety of factors including economic data, Curis' earnings reports, geopolitical events, and overall market trends.
  

Curis Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Curis can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at finance.yahoo.com         
Curis Provides Second Quarter 2023 Business Update
Yahoo News
over a year ago at seekingalpha.com         
Curis Q2 2023 Earnings Preview
seekingalpha News
over a year ago at news.google.com         
Aerovate Therapeutics August 2023 Corporate Presentation - Marketscreener.com
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
Yahoo News
over a year ago at news.google.com         
Curis A Speculative Microcap Worth A Second Look - Seeking Alpha
Google News at Macroaxis
over a year ago at medcitynews.com         
FDA Lifts Partial Hold on Curis Drug, Clearing Way for Phase 2 Leukemia Study
news
over a year ago at benzinga.com         
Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study
benzinga news
over a year ago at benzinga.com         
Why Curis Shares Are Nosediving Thursday
benzinga news
over a year ago at seekingalpha.com         
Curis launches 15.1M registered direct offering
seekingalpha News
over a year ago at seekingalpha.com         
Curis stock falls as FDA lifts partial clinical hold
seekingalpha News
over a year ago at finance.yahoo.com         
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
Yahoo News
over a year ago at finance.yahoo.com         
Curis Announces 15.1 Million Registered Direct Offering
Yahoo News
over a year ago at news.google.com         
Aerovate Therapeutics July 2023 Corporate Presentation - Marketscreener.com
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Investors in Curis have unfortunately lost 50 percent over the last five years
Yahoo News
Far too much social signal, news, headlines, and media speculation about Curis that are available to investors today. That information is available publicly through Curis media outlets and privately through word of mouth or via Curis internal channels. However, regardless of the origin, that massive amount of Curis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Curis news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Curis relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Curis' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Curis alpha.

Curis Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 2406 shares by James Dentzer of Curis at 3.18 subject to Rule 16b-3
09/19/2024
2
Curis Inc Q2 2024 Earnings Call Highlights Promising Clinical Progress Amid Financial ...
10/09/2024
3
Acquisition by Borgman Anne Elizabeth of 25000 shares of Curis subject to Rule 16b-3
10/11/2024
4
Curis Stock Plummets Over 5 percent Amid Lack of Institutional Ratings
10/31/2024
5
Curis up 4 percent on emavusertib data in myelodysplastic syndrome
11/05/2024
6
Mirum Pharmaceuticals, Inc. Reports Q3 Loss, Tops Revenue Estimates
11/12/2024
7
Curis Inc Q3 2024 Everything You Need to Know Ahead of Earnings
11/13/2024
8
Curis Provides Third Quarter 2024 Business Update
11/14/2024
9
Curis Inc Q3 2024 Earnings Call Highlights Navigating Financial Challenges and ...
11/15/2024
10
Curis Inc Stock Surges 5.46 percent Amid Positive Analyst Ratings
11/27/2024

Additional Tools for Curis Stock Analysis

When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.